A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 36
Summary
- Conditions
- Leukemia, Myelocytic, Acute
- Myelodysplastic Syndrome (MDS)
- Myelodysplastic/Myeloproliferative Neoplasm
- Myelofibrosis
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02158858
- Collaborators
- The Leukemia and Lymphoma Society
- Investigators
- Study Director: Debbie Johnson Constellation Pharmaceuticals
Get Well Soon